Media coverage about Vericel (NASDAQ:VCEL) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vericel earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.9527496850323 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s analysis:

Several analysts recently commented on the company. Needham & Company LLC lowered their target price on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, August 8th. LADENBURG THALM/SH SH upgraded Vericel from a “neutral” rating to a “buy” rating in a research report on Monday, July 16th. BTIG Research restated a “buy” rating and issued a $17.00 target price on shares of Vericel in a research report on Wednesday, May 9th. BidaskClub cut Vericel from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 15th. Finally, ValuEngine upgraded Vericel from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.00.

VCEL opened at $10.95 on Tuesday. Vericel has a 12 month low of $3.30 and a 12 month high of $14.75. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.48 and a current ratio of 7.72. The company has a market capitalization of $474.26 million, a P/E ratio of -21.90 and a beta of 3.18.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. The company had revenue of $19.01 million for the quarter, compared to analysts’ expectations of $18.51 million. research analysts expect that Vericel will post -0.34 earnings per share for the current fiscal year.

In other news, Director Paul K. Wotton sold 30,000 shares of Vericel stock in a transaction on Monday, June 18th. The stock was sold at an average price of $12.06, for a total transaction of $361,800.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $60,300. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.70% of the stock is currently owned by company insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Further Reading: Average Daily Trade Volume Explained

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.